In conjunction with a recent study that discovered that another BCL2 inhibitor, ABT199, can be used in combination with Enz for the treatment of EnzR CRPC [24], we further dissected the ABT263 molecular mechanisms and showed here that ABT263 can decrease AR/ARv7 protein expression to increase Enz sensitivity of both EnzS and EnzR PCa cells. The gene discussed is BCL2; the disease is posterior cortical atrophy.